A Cell Therapy company who are developing a unique personalised approach to curing cancer using a proprietary bioinformatics and sequencing platform are recruiting for a Senior Bioinformatician to be based in their Stevenage Laboratories. As a Senior member of the team you will be providing experimental design, data modelling and analysis expertise to drive forward their research portfolio.
The Senior Bioinformatician with sits within their Sequencing and Analytics Team who are responsible for the analysis of large biological data sets. With the aim to improve these by increasing the quality of tumour samples and streamlining sequencing protocols. To develop ways to enhance their ability to identify the relevant clonal neoantigens to develop personalised therapies.
The role of the Senior Bioinformatician, who will be working alongside the group leader, to lead exploratory research into the large and complex datasets. Working with clinicians and scientists to develop and test hypotheses whilst prototyping analytical approaches. Providing support to different groups to support their NGS projects to improve their sequencing workflow.
As this is a senior role you will be working autonomously, using creative and innovative approaches to solve complex problems. This is an emerging team in a growing company meaning there is initial growth in the role followed by excellent longer-term progression opportunities.
Desired Skills and Competencies:
For this opportunity, you will be at least educated to PhD or MSc with experience of analysing large data sets using R, and / or Python languages in academia or industry. With a deep understanding of cancer genomics with with prior experience of working data generated from NGS / Next generation Sequencing. You will need to have experience of working with data modelling and statistical analysis preferably applied to Next Generation Sequencing.
The company are developing an approach to curing cancer that is different and enables them to meet unmet needs. They are develoing nobvel immunotherapies that are targeting the protein markers that are unique to each person and expressed on the surface of each cancer cell. These are called Neoantigens and their approach is to sequencing data from each patient sample in conjunction with their bioinformatics platform to identify and then develop a cell therapy to target the neoantigens. This way a personalised treatment can be developed that targets.